

- Existing insulin therapy has certain limitations, which do not allow efficient glycemic control without compromising on safety and tolerability
- Insulin degludec is a truly basal, ultra long acting insulin, with a half-life of nearly 26 hours, and a duration of action for 42 hours
- Insulin degludec is associated with less variability and less hypoglycemia
- It can be dosed at any time of the day, and does not need to be taken at the same time each day
- Insulin degludec represents a major advance in insulin pharmacotherapeutics

This summary slide represents the opinions of the authors, and not necessarily the opinions of the publisher or editorial board. This material has been peer reviewed. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online.